

Grant of options

Oxford, UK - 16 May 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, announces that on 16 May 2025, nil-cost share options over ordinary shares of 50 pence each in the Company were granted under the OXB 2024 Long Term Incentive Plan ("LTIP") and OXB 2024 Deferred Bonus Plan ("DBP").

2025 Grants

Type	Name of individual	Title	Number of share options granted under the plans prior to 2025 award	Number of share options granted under 2025 award	Total share options subsequently held under plans	Percentage of current issued share capital under plans
LTIP	Frank Mathias	Chief Executive Officer	580,291	350,204	930,495	0.88%
DBP	Frank Mathias	Chief Executive Officer	930,495	70,803	1,001,298	0.94%
LTIP	Lucinda Crabtree	Chief Financial Officer	170,113	201,095	371,208	0.35%
DBP	Lucinda Crabtree	Chief Financial Officer	371,208	15,733	386,941	0.36%
LTIP	Natalie Walter	Group General Counsel	201,987	73,360	275,347	0.26%
DBP	Natalie Walter	Group General Counsel	275,347	11,448	286,795	0.27%
LTIP RSU	Natalie Walter	Group General Counsel	286,795	14,204	300,999	0.28%
LTIP	Sebastien Ribault	Chief Business Officer	125,309	80,029	205,338	0.19%
DBP	Sebastien Ribault	Chief Business Officer	205,338	14,879	220,217	0.21%
LTIP RSU	Sebastien Ribault	Chief Business Officer	220,217	15,495	235,712	0.22%
LTIP	Lisa Doman	Chief People Officer	140,453	62,585	203,038	0.19%
DBP	Lisa Doman	Chief People Officer	203,038	10,693	213,731	0.20%
LTIP RSU	Lisa Doman	Chief People Officer	213,731	12,118	225,849	0.21%

		Officer				
LTIP	Thierry Courmez	Chief Operating Officer	118,007	74,132	192,139	0.18%
DBP	Thierry Courmez	Chief Operating Officer	192,139	12,336	204,475	0.19%
LTIP RSU	Thierry Courmez	Chief Operating Officer	204,475	14,353	218,828	0.21%
LTIP	Kyriacos Mitrophanous	Chief Innovation Officer	232,084	70,699	302,783	0.29%
DBP	Kyriacos Mitrophanous	Chief Innovation Officer	302,783	12,852	315,635	0.30%
LTIP RSU	Kyriacos Mitrophanous	Chief Innovation Officer	315,635	13,689	329,324	0.31%
LTIP	Mark Caswell	Site Head of UK Operations	127,896	79,168	207,064	0.20%
LTIP RSU	Mark Caswell	Site Head of UK Operations	207,064	15,329	222,393	0.21%
LTIP RSU	Sabine Sydow	Chief of Staff	20,115	9,780	29,895	0.03%
LTIP RSU	Stephanie Colloud	Site Head of France Operations	-	12,634	12,634	0.01%

The Remuneration Committee has determined that EBITDA margin and revenue growth are the key metrics aligned with OXB's growth strategy, relevant to LTIP grant only. Details of the targets for the EBITDA margin and revenue growth measures are included in the 2024 Directors' Remuneration Report.

The Notification of Dealing Forms set out below, which all represent initial notifications in respect of the grants mentioned above, are provided in accordance with the requirements of the EU Market Abuse Regulation.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Frank Mathias	
2.	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP Award	
		Price	Volume
		Nil	350,204
d)	Aggregated information - Aggregate volume	Awards granted over 350,204 shares in total	
	Price	N/A	

e)	Date of the transaction	2025-05-16
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Frank Mathias	
2.	Reason for the notification		
a)	Position/status	Chief Executive Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 DBP Award	
		Price	Volume
		Nil	70,803
d)	Aggregated information - Aggregate volume - Price	Awards granted over 70,803 shares in total N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")						
a)	Name	Lucinda Crabtree					
2.	Reason for the notification						
a)	Position/status	Chief Financial Officer					
b)	Initial notification/ amendment	Initial Notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.					
c)	Price(s) and volumes(s)	2025 LTIP Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>201,095</td></tr></table>		Price	Volume	Nil	201,095
Price	Volume						
Nil	201,095						
d)	Aggregated information - Aggregate volume - Price	Awards granted over 201,095 shares in total N/A					
e)	Date of the transaction	2025-05-16					
f)	Place of the transaction	Outside of trading venue					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")	
a)	Name	Lucinda Crabtree

2.	Reason for the notification						
a)	Position/status	Chief Financial Officer					
b)	Initial notification/ amendment	Initial Notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards.					
c)	Price(s) and volumes(s)	2025 DBP Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>15,733</td></tr></table>		Price	Volume	Nil	15,733
Price	Volume						
Nil	15,733						
d)	Aggregated information - Aggregate volume - Price	Awards granted over 15,733 shares in total N/A					
e)	Date of the transaction	2025-05-16					
f)	Place of the transaction	Outside of trading venue					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")						
a)	Name	Natalie Walter					
2.	Reason for the notification						
a)	Position/status	General Counsel					
b)	Initial notification/ amendment	Initial Notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.					
c)	Price(s) and volumes(s)	2025 LTIP Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>73,360</td></tr></table>		Price	Volume	Nil	73,360
Price	Volume						
Nil	73,360						
d)	Aggregated information - Aggregate volume - Price	Awards granted over 73,360 shares in total N/A					
e)	Date of the transaction	2025-05-16					
f)	Place of the transaction	Outside of trading venue					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")	
a)	Name	Natalie Walter
2.	Reason for the notification	
a)	Position/status	General Counsel
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer	
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument	Ordinary Shares of 50 pence each

	financial instrument	ISIN: GB00BDFBVT43	
	Identification code		
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 DBP Award	
		Price	Volume
		Nil	11,448
d)	Aggregated information	Awards granted over 11,448 shares in total	
	- Aggregate volume		
	- Price	N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Natalie Walter	
2.	Reason for the notification		
a)	Position/status	General Counsel	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP RSU Award	
		Price	Volume
		Nil	14,204
d)	Aggregated information	Awards granted over 14,204 shares in total	
	- Aggregate volume		
	- Price	N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Sebastien Ribault	
2.	Reason for the notification		
a)	Position/status	Chief Business Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP Award	
		Price	Volume
		Nil	80,029
d)	Aggregated information - Aggregate volume	Awards granted over 80.029 shares in total	

	- Price	N/A
e)	Date of the transaction	2025-05-16
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")						
a)	Name	Sebastien Ribault					
2.	Reason for the notification						
a)	Position/status	Chief Business Officer					
b)	Initial notification/ amendment	Initial Notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards.					
c)	Price(s) and volumes(s)	2025 DBP Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>14,879</td></tr></table>		Price	Volume	Nil	14,879
Price	Volume						
Nil	14,879						
d)	Aggregated information - Aggregate volume - Price	Awards granted over 14,879 shares in total N/A					
e)	Date of the transaction	2025-05-16					
f)	Place of the transaction	Outside of trading venue					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")						
a)	Name	Sebastien Ribault					
2.	Reason for the notification						
a)	Position/status	Chief Business Officer					
b)	Initial notification/ amendment	Initial Notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.					
c)	Price(s) and volumes(s)	2025 LTIP RSU Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>15,495</td></tr></table>		Price	Volume	Nil	15,495
Price	Volume						
Nil	15,495						
d)	Aggregated information - Aggregate volume - Price	Awards granted over 15,495 shares in total N/A					
e)	Date of the transaction	2025-05-16					
f)	Place of the transaction	Outside of trading venue					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")	
a)	Name	Lisa Doman
2.	Reason for the notification	
a)	Position/status	Chief People Officer

b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP Award	
		Price	Volume
		Nil	62,585
d)	Aggregated information - Aggregate volume - Price	Awards granted over 62,585 shares in total N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Lisa Doman	
2.	Reason for the notification		
a)	Position/status	Chief People Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 DBP Award	
		Price	Volume
		Nil	10,693
d)	Aggregated information - Aggregate volume - Price	Awards granted over 10.693 shares in total N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")	
a)	Name	Lisa Doman
2.	Reason for the notification	
a)	Position/status	Chief People Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer	
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's

b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP RSU Award	
		Price	Volume
		Nil	12,118
d)	Aggregated information - Aggregate volume - Price	Awards granted over 12,118 shares in total N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Thierry Courmez	
2.	Reason for the notification		
a)	Position/status	Chief Operating Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP Award	
		Price	Volume
		Nil	74,132
d)	Aggregated information - Aggregate volume - Price	Awards granted over 74,132 shares in total N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Thierry Courmez	
2.	Reason for the notification		
a)	Position/status	Chief Operating Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 DBP Award	
		Price	Volume
		Nil	12,336
d)	Aggregated information - Aggregate volume - Price	Awards granted over 12,336 shares in total N/A	

e)	Date of the transaction	2025-05-16
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")						
a)	Name	Thierry Courmez					
2.	Reason for the notification						
a)	Position/status	Chief Operating Officer					
b)	Initial notification/ amendment	Initial Notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.					
c)	Price(s) and volumes(s)	2025 LTIP RSU Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>14,353</td></tr></table>		Price	Volume	Nil	14,353
Price	Volume						
Nil	14,353						
d)	Aggregated information - Aggregate volume - Price	Awards granted over 14,353 shares in total N/A					
e)	Date of the transaction	2025-05-16					
f)	Place of the transaction	Outside of trading venue					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Kyriacos Mitrophanous	
2.	Reason for the notification		
a)	Position/status	Chief Innovation Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP Award	
		Price	Volume
		Nil	70,699
d)	Aggregated information - Aggregate volume - Price	Awards granted over 70,699 shares in total N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")	
a)	Name	Kyriacos Mitrophanous
2.	Reason for the notification	
a)	Position/status	Chief Innovation Officer
b)	Initial notification/ amendment	Initial Notification

3.	Initial notification/ amendment	Initial notification				
3.	Details of the Issuer					
a)	Name	Oxford Biomedica plc				
b)	LEI code	213800S1GVQNXQ15K851				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument	Ordinary Shares of 50 pence each				
	Identification code	ISIN: GB00BDFBVT43				
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Deferred Bonus Plan. No consideration was paid for the grant of awards.				
c)	Price(s) and volumes(s)	2025 DBP Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>12,852</td></tr></table>	Price	Volume	Nil	12,852
Price	Volume					
Nil	12,852					
d)	Aggregated information - Aggregate volume - Price	Awards granted over 12,852 shares in total N/A				
e)	Date of the transaction	2025-05-16				
f)	Place of the transaction	Outside of trading venue				

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Kyriacos Mitrophanous	
2.	Reason for the notification		
a)	Position/status	Chief Innovation Officer	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP RSU Award	
		Price	Volume
		Nil	13,689
d)	Aggregated information - Aggregate volume - Price	Awards granted over 13,689 shares in total N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")	
a)	Name	Mark Caswell
2.	Reason for the notification	
a)	Position/status	Site Head of UK Operations
b)	Initial notification/ amendment	Initial notification
3.	Details of the Issuer	
a)	Name	Oxford Biomedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument	Ordinary Shares of 50 pence each

	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP Award	
		Price	Volume
		Nil	79,168
d)	Aggregated information	79,168	
	- Aggregate volume		
	- Price	N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")						
a)	Name	Mark Caswell					
2.	Reason for the notification						
a)	Position/status	Site Head of UK Operations					
b)	Initial notification/ amendment	Initial notification					
3.	Details of the Issuer						
a)	Name	Oxford Biomedica plc					
b)	LEI code	213800S1GVQNXQ15K851					
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted						
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43					
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.					
c)	Price(s) and volumes(s)	2025 LTIP RSU Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>15,329</td></tr></table>		Price	Volume	Nil	15,329
Price	Volume						
Nil	15,329						
d)	Aggregated information - Aggregate volume - Price	15,329 N/A					
e)	Date of the transaction	2025-05-16					
f)	Place of the transaction	Outside of trading venue					

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")					
a)	Name	Sabine Sydow				
2.	Reason for the notification					
a)	Position/status	Chief of Staff				
b)	Initial notification/ amendment	Initial Notification				
3.	Details of the Issuer					
a)	Name	Oxford Biomedica plc				
b)	LEI code	213800S1GVQNXQ15K851				
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted					
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43				
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.				
c)	Price(s) and volumes(s)	2025 LTIP RSU Award <table><tr><td>Price</td><td>Volume</td></tr><tr><td>Nil</td><td>9,780</td></tr></table>	Price	Volume	Nil	9,780
Price	Volume					
Nil	9,780					
d)	Aggregated information - Aggregate volume	Awards granted over 9,780 shares in total				

	- Price	N/A
e)	Date of the transaction	2025-05-16
f)	Place of the transaction	Outside of trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")		
a)	Name	Stephanie Colloud	
2.	Reason for the notification		
a)	Position/status	Site Head of France Operations	
b)	Initial notification/ amendment	Initial Notification	
3.	Details of the Issuer		
a)	Name	Oxford Biomedica plc	
b)	LEI code	213800S1GVQNXQ15K851	
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary Shares of 50 pence each	
	Identification code	ISIN: GB00BDFBVT43	
b)	Nature of the transaction	Grant of awards over Ordinary Shares under the Company's Long Term Incentive Plan. No consideration was paid for the grant of awards.	
c)	Price(s) and volumes(s)	2025 LTIP RSU Award	
		Price	Volume
		Nil	12,634
d)	Aggregated information	Awards granted over 12,634 shares in total	
	- Aggregate volume		
	- Price	N/A	
e)	Date of the transaction	2025-05-16	
f)	Place of the transaction	Outside of trading venue	

-Ends-

Enquiries:

OXB:

Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

About OXB

OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.

OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.

OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities

across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on [LinkedIn](#) and [YouTube](#).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DSHDZGMKVVLGKZM